WVP
NYMX

Worth Venture Partners’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Worth Venture Partners’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-101,999
Closed -$250K – 135
2020
Q3 		$250K Buy
+101,999
New +$297K 0.21% 86

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Worth Venture Partners's NYMX Position: Q4 2020 in Review

Worth Venture Partners sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2020, closing a stake of 101,999 shares — an estimated $250K sold.

Worth Venture Partners first reported a position in NYMX in Q3 2020 and held it in 1 quarter. The position peaked at $250K in Q3 2020. 58 funds tracked by Wall St. Rank hold NYMX as of Q4 2020.

  • Worth Venture Partners reported no remaining Nymox Pharmaceutical Corp position as of Q4 2020 after selling out during the quarter.
  • Worth Venture Partners sold 101,999 Nymox Pharmaceutical Corp shares in Q4 2020, an estimated $250K.
  • Worth Venture Partners first reported a position in Nymox Pharmaceutical Corp in Q3 2020 and held it in 1 quarter.
  • Worth Venture Partners's Nymox Pharmaceutical Corp position peaked at $250K in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2020.

Based on Worth Venture Partners's 13F filing for Q4 2020, filed 17 Feb 2021.